Plunkett Research Online: Critical Outcome Techno

CRITICAL OUTCOME TECHNO (COT:TSX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel ora.....



Critical Outcome Techno
Ticker: COT
Exchange: TSX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 519 858-5157
Fax: 519 858-5179
Address: 82 Richmond Street East
The Canadian Venture Building
Toronto, ON M5C1P1 Canada

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Vaccines, Skin Replacement Products and Biologicals Manufacturing
Contacts Description

Alison Silva CEO/Director/President
Victor Hugo CFO
See More
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel ora.....See More See More

Auditor: SDVC LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2019 2018 2017 2016 2015 2014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: